Cargando…
国产苯达莫司汀联合利妥昔单抗一线治疗惰性B细胞淋巴瘤及老年套细胞淋巴瘤的疗效及安全性——多中心、前瞻性、Ⅱ期临床研究
OBJECTIVE: This study aimed to assess the efficacy and safety of bendamustine in combination with rituximab(BR regimen)for the treatment of newly diagnosed indolent B-cell non-Hodgkin's lymphoma(B-iNHL)and elderly mantle cell lymphoma(eMCL). METHODS: From December 1, 2020 to September 10, 2022,...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509620/ https://www.ncbi.nlm.nih.gov/pubmed/37749033 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.07.004 |
Ejemplares similares
-
苯达莫司汀联合利妥昔单抗一线治疗惰性B细胞非霍奇金淋巴瘤和套细胞淋巴瘤的真实世界研究
Publicado: (2023) -
BTK抑制剂联合苯达莫司汀、利妥昔单抗一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的疗效及安全性
Publicado: (2023) -
含苯达莫司汀预处理方案自体造血干细胞移植治疗淋巴瘤的近期疗效及安全性
Publicado: (2022) -
苯达莫司汀治疗B细胞性非霍奇金淋巴瘤的研究进展
Publicado: (2015) -
CD5阴性套细胞淋巴瘤一例报告及文献复习
Publicado: (2015)